Urogen Pharma Ltd at Goldman Sachs Healthcare Conference Transcript
Okay. We'll continue with the next session. I'm Paul Choi, and I cover the mid-cap biotech sector here at the firm. And it's our pleasure to have UroGen here for this session. Joining me is Liz Barrett, CEO.
Questions & Answers
Maybe what we'll do, Liz is let you kick it off with maybe some high-level comments on what are your strategic priorities for the remainder of 2026 and going into 2027? And what are you seeking to accomplish with UroGen here over the near term?
No, great question. And we -- I'm glad you started it with what's your sort of strategy and focus, right? Because I think one of the things we're starting to do is shift actually from the very, very near term to more of a longer-term look at the company and where we're going as a company.
As you know and most people know, we launched ZUSDURI, which was our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
